跳至主要内容
临床试验/CTRI/2010/091/000552
CTRI/2010/091/000552已完成3 期

A Double Blind, Randomized, Parallel Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo as a Urinary Analgesic for Short Term Treatment in Female Subjects Suffering from Pain or Burning when Passing Urine Associated with Uncomplicated Urinary Tract Infections (uUTI)

Amneal Pharmaceuticals0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Inclusion Criteria:
  • 1. Females, 18 years of age or older
  • 2. Able to give written informed consent
  • 3 Diagnosis of uncomplicated urinary tract infection
  • 4. Must have one of the following uUTI diagnosis - Cystitis or Urethritis
  • 5. A positive urine dipstick showing nitrate or leukocyte esterase (LE)
  • 6. Negative Urine Pregnancy Test (if applicable)
  • 7. Must have one or both of the following symptom of - pain upon urination, burning upon urination
  • 8. In addition, any one of the following symptoms that subject reports
  • a) Not being able to empty bladder completely
  • b) Pain or discomfort in lower abdomen, or pelvic areas caused by UTI
  • c) Frequent urge to urinate
  • d) Blood in urine
  • e) Low back pain caused by your urinary tract infection

排除标准

  • Exclusion Criteria:
  • 1. Any diagnosis of a urinary tract or kidney disorder that is not a uUTI
  • 2. A diagnosis of Pyelonephritis (kidney infections when lower uUTI spreads to the upper tract)
  • 3. Women with a history of prior use of phenazopyridine hydrochloride
  • 4. Women who have taken any systemic anti-infectives within seven days of study participation.
  • 5. Women with a history of G-6-PD deficiency or hemolytic anemia
  • 6. Women who have a known history of anatomical genitourinary (GU) anomalies or GU surgery within the past 6 months
  • 7. Women of child bearing age who do not consent to a pregnancy test
  • 8. Women who are lactating
  • 9. Chronic infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound or cystoscopy
  • 10. Subjects with clinically significant abnormal results or finding on the screening physcal examination, laboratory tests, vital signs or ECG
  • 11. Subjects unabele to comprehend the language of the informed consent and the self evaluation scales
  • 12. Subject with serious acute illness (e.g. pneumonia) or an untreated or unstable medical illness that would likely interfere with assessments of uUTI
  • 13. Subjects who have received an investigational medication as a part of a drug trial 3 months prior to the baseline study visit
  • 14. Subjects with a history of severe drug allergy or hypersensitivity
  • 15. Subjects with a known sensitivity to Phenazopyridine, Hyoscyamine, Butabarbital and antibiotics
  • 16. Employees of the investigator or institution who have direct involvement in the trial or other trials under the direction of the investigator or their associates

研究者

相似试验

To evaluate the safety and efficacy of... | 临床试验